Neutral
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside?
Vertex Pharmaceuticals dominates the cystic fibrosis (CF) market, but faces patent expirations in the late 2030s. The company is diversifying its pipe...